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Background
Angioedema of the upper airway is a life-threatening
Emergency Department (ED) presentation with many
etiologies. Angiotensin converting enzyme-inhibitor
(ACE-I) use is one cause of non-mast cell mediated
angioedema. As the use of this medication class increases
with our aging population, it is important to characterize
the presentation and management of ACE-I induced
angioedema (AAE), a rare but potentially severe side
effect of this commonly prescribed medication class. The
objectives of this study were to describe the incidence
and management of AAE in the ED and to identify any
epinephrine-induced morbidity.
Methods
A retrospective medical record review was conducted of
all patients presenting to two Canadian tertiary care EDs
between July 2007 and March 2012. Patients were identi-
fied for inclusion using the International Classification
of Diseases, 10th revision discharge diagnostic codes of
T782, T783, T784, T886, T887 and D841. Records were
excluded from study if there was no visible swelling
documented on the medical record, or if swelling was
found to be secondary to non-systemic reaction to an
insect sting, trauma or irritant exposure.
Results
Of 1702 medical records identified through our inclusion
criteria, 1175 were excluded for reasons cited above. Of
the remaining 527 ED visits, an inciting cause was identi-
fied in 48.8% (n=257), based on our a priori definitions.
Of these, the most common identifiable etiology was AAE
(33.1%, n= 85). The most common locations of swelling in
patients with AAE were the tongue or lips, found in 51%
and 40% of subjects, respectively. Common ED medica-
tions used to manage AAE included diphenhydramine
(63.5%, n=54), corticosteroids (50.6%, n=43) and ranitidine
(31.8%, n= 27). Epinephrine was administered in 18 AAE
patients (21.2%), 5 of whom received repeated doses.
In two of these patients, morbidity developed shortly after
epinephrine administration, causing myocardial ischemia
or dysrhythmia. Four AAE patients (4.7%) required
admission to hospital and one required endotracheal
intubation. There was no associated mortality.
Conclusions
Our study demonstrates that AAE is the most common
identifiable etiology of angioedema of patients presenting
to the ED. Management of AAE commonly includes anti-
histamines and corticosteroids. Concerningly, epinephrine
use is common. Many patients started on ACE-Is are at
high risk for developing complications from epinephrine
administration, which has limited physiologic rationale
for use in the setting of AAE. More research is required
to better delineate epinephrine’s role in this vulnerable
patient population and identify other therapeutic options.
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